Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: SCIO Scios Inc.

No earlier versions found for this Subject.

Return to SCIO Scios Inc.

Scios & Wyeth-Ayerst have announced an agreement to develop FIBLAST for neurological and cardiovascular disorders.

Wyeth-Ayerst, the pharmaceutical division of American Home Products, will make a $12million upfront payment in cash and will also pay Scios up to $32million in milestone payments upon achievement of all key development events. In addition, Wyeth-Ayerst will provide a $12million line of credit that Scios may draw upon from time to time to fund expansion of its manufacturing facilities for FIBLAST.